Patents by Inventor John E. Macor

John E. Macor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INDOLE CARBOXAMIDE COMPOUNDS
    Publication number: 20190119245
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: February 1, 2018
    Publication date: April 25, 2019
    Inventors: Qingjie Liu, Scott Hunter Watterson, John E. Macor, Khehyong Ngu, Saleem Ahmad
  • SELECTIVE NR2B ANTAGONISTS
    Publication number: 20190117638
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 25, 2019
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Carbazole derivatives
    Patent number: 10266491
    Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, and R7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: April 23, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Saleem Ahmad, Douglas G. Batt, Qingjie Liu, John E. Macor, Joseph A. Tino, Scott Hunter Watterson, Satheesh Kesavan Nair, Tarun Kumar Maishal
  • Aryl lactam kinase inhibitors
    Patent number: 10253027
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: April 9, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Joanne J. Bronson, Carolyn Diane Dzierba, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani
  • Biaryl kinase inhibitors
    Patent number: 10246469
    Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: April 2, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Joanne J. Bronson, Ling Chen, Jonathan L. Ditta, Carolyn Diane Dzierba, Prasada Rao Jalagam, Guanglin Luo, John E. Macor, Tarun Kumar Maishal, Susheel Jethanand Nara, Ramkumar Rajamani, Ramesh Kumar Sistla, Soodamani Thangavel
  • Heteroaryl substituted aminopyridine compounds
    Patent number: 10202390
    Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, or triazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: February 12, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: John V. Duncia, Daniel S. Gardner, John Hynes, John E. Macor, Satheesh Kesavan Nair, Venkatram Reddy Paidi, Joseph B. Santella, Kandhasamy Sarkunam, Ramesh Kumar Sistla, Subba Rao Polimera, Hong Wu
  • BIARYL KINASE INHIBITORS
    Publication number: 20190040080
    Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
    Type: Application
    Filed: September 29, 2016
    Publication date: February 7, 2019
    Inventors: Joanne J. BRONSON, Ling CHEN, Jonathan L. DITTA, Carolyn Diane DZIERBA, Prasada Rao JALAGAM, Guanglin LUO, John E. MACOR, Tarun Kumar MAISHAL, Susheel Jethanand Nara, Ramkumar RAJAMANI, Ramesh Kumar SISTLA, Soodamani THANGAVEL
  • Fused pyridines as kinase inhibitors
    Patent number: 10174044
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Susheel Jethanand Nara, Carolyn Diane Dzierba, John E. Macor, Joanne J. Bronson, Rajamani Ramkumar, Tarun Kumar Maishal, Maheswaran Sivasamban Karatholuvhu, Soodamani Thangavel, Kamalraj Thiyagarajan
  • Biaryl kinase inhibitors
    Patent number: 10155760
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: December 18, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • BIARYL KINASE INHIBITORS
    Publication number: 20180346440
    Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
    Type: Application
    Filed: September 29, 2016
    Publication date: December 6, 2018
    Inventors: Joanne J. Bronson, Ling Chen, Jonathan L. Ditta, Carolyn Diane Dzierba, Prasada Rao Jalagam, Guanglin Luo, John E. Macor, Tarun Kumar Maishal, Susheel Jethanand Nara, Ramkumar Rajamani, Ramesh Kumar Sistla, Soodamani Thangavel
  • SELECTIVE NR2B ANTAGONISTS
    Publication number: 20180312491
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: October 13, 2016
    Publication date: November 1, 2018
    Inventors: Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, Grandhi Venkat Ram Krishna Mohan Gupta, John E. Macor
  • SELECTIVE NR2B ANTAGONISTS
    Publication number: 20180312495
    Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMD A) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: October 13, 2016
    Publication date: November 1, 2018
    Inventors: Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, John E. Macor
  • [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
    Patent number: 10071079
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: September 11, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Ramesh Kumar Sistla
  • (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20180250316
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 6, 2018
    Inventors: Lorin A. Thompson, III, John E. Macor
  • SELECTIVE NR2B ANTAGONISTS
    Publication number: 20180250283
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 6, 2018
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Heterocyclic kinase inhibitors
    Patent number: 10035777
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: July 31, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor, Bireshwar Dasgupta, Susheel Jethanand Nara, Vivekananda M. Vrudhula, Senliang Pan, Richard A. Hartz, Ramkumar Rajamani
  • HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS
    Publication number: 20180179213
    Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, or triazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
    Type: Application
    Filed: June 23, 2016
    Publication date: June 28, 2018
    Inventors: John V. DUNCIA, Daniel S. Gardner, John Hynes, John E. Macor, Satheesh Kesavan Nair, Venkatram Reddy Paidi, Joseph B. Santella, Kandhasamy Sarkunam, Ramesh Kumar Sistla, Subba Rao Polimera, Hong Wu
  • FUSED PYRIDINES AS KINASE INHIBITORS
    Publication number: 20180141956
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: April 4, 2016
    Publication date: May 24, 2018
    Inventors: Susheel Jethanand Nara, Carolyn Diane Dzierba, John E. Macor, Joanne J. Bronson, Rajamani Ramkumar, Tarun Kumar Maishal, Maheswaran Sivasamban Karatholuvhu, Soodamani Thangavel, Kamalraj Thiyagarajan
  • BIARYL KINASE INHIBITORS
    Publication number: 20180134704
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 17, 2018
    Inventors: Guanglin Luo, Ling Chen, Carolyn Diane Dzierba, Jonathan L. Ditta, John E. Macor, Joanne J. Bronson
  • SELECTIVE NR2B ANTAGONISTS
    Publication number: 20180110766
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: December 19, 2017
    Publication date: April 26, 2018
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor